⚠ Evidence warning: Clinical trials or other evidence do not support the claims that reactive hypoglycemia reflects impaired alanine-mediated blood sugar recovery, that the alanine load test detects impairment earlier than standard liver markers, and that a 7-10 percent weight loss reverses early fibrosis. This page keeps it as a report of what people, websites or other media say.

Alanine for Liver Function (Alanine Aminotransferase, ALT)

Liver Function — scientific infographic poster

Alanine aminotransferase (ALT, historically SGPT) is the single most-ordered biomarker on every standard liver panel in clinical medicine worldwide. The enzyme is named after alanine because it catalyzes the central transamination between alanine and alpha-ketoglutarate to produce pyruvate and glutamate — the entry step into hepatic gluconeogenesis. Alanine aminotransferase is present at extraordinarily high concentrations inside hepatocytes (roughly 3,000-fold higher than serum levels) and at very low concentrations in all other tissues. The combination of liver-specific localization and high intracellular concentration makes serum alanine aminotransferase the most sensitive routine biochemical marker of hepatocyte injury: even modest liver-cell damage releases enough enzyme to produce measurable serum elevations. The 21st-century transformation of population liver disease — the global emergence of non-alcoholic fatty liver disease (NAFLD), now estimated at about 30% of adults worldwide — has elevated alanine aminotransferase from a hepatology workup tool to a routine population health screen for metabolic dysfunction. This page covers the biochemistry of alanine aminotransferase, the interpretation of alanine aminotransferase elevation patterns, the aspartate aminotransferase (AST):alanine aminotransferase ratio in distinguishing different liver pathologies, modern healthy-range cutoffs, non-alcoholic fatty liver disease epidemiology, drug-induced liver injury, and the practical workup of an isolated alanine aminotransferase elevation.


Table of Contents

  1. Alanine Aminotransferase — The Enzyme Named After Alanine
  2. Why Alanine Aminotransferase Is the Most Liver-Specific Routine Marker
  3. The Normal Range Controversy (40 U/L vs 19/30 U/L)
  4. Interpretation by Magnitude of Alanine Aminotransferase Elevation
  5. The Aspartate Aminotransferase:Alanine Aminotransferase Ratio — Alcoholic vs Non-Alcoholic Patterns
  6. Non-Alcoholic Fatty Liver Disease — The Global Liver Disease Epidemic
  7. Recent Drug Trials in Steatohepatitis With Liver Scarring
  8. Drug-Induced Liver Injury (DILI)
  9. Viral Hepatitis Pattern
  10. Practical Workup of an Isolated Alanine Aminotransferase Elevation
  11. The Alanine Load Test for Hepatic Function
  12. Cautions
  13. Key Research Papers
  14. Connections
  15. Featured Videos

Alanine Aminotransferase — The Enzyme Named After Alanine

Alanine aminotransferase (ALT, EC 2.6.1.2) is one of the two principal aminotransferases of clinical interest, the other being aspartate aminotransferase (AST, EC 2.6.1.1, historically SGOT). Both enzymes use pyridoxal-5-phosphate (the active form of vitamin B6) as cofactor and catalyze reversible transamination reactions. Alanine aminotransferase catalyzes:

L-alanine + alpha-ketoglutarate ↔ pyruvate + L-glutamate

This is the rate-limiting entry step for alanine's contribution to hepatic gluconeogenesis. In liver, alanine aminotransferase runs this reaction in the forward direction as written (consuming alanine to produce pyruvate for gluconeogenesis); in muscle, it runs in reverse (consuming pyruvate and glutamate to produce alanine for nitrogen export). The directional preference depends on cell-specific concentrations of the four reactants and on the cell's gluconeogenic vs gluconeogenic-suppressed state.

Alanine aminotransferase exists in two isozymic forms in humans: ALT1 (cytosolic, encoded by GPT) and ALT2 (mitochondrial, encoded by GPT2). The cytosolic ALT1 is the predominant form in liver and the form that is measured on standard liver panels. The mitochondrial ALT2 is more highly expressed in muscle, heart, and brain — muscle being where the alanine shuttle described above begins — and contributes only modestly to serum activity in healthy adults.

The historical name SGPT (serum glutamic-pyruvic transaminase) reflects the products of the reaction (glutamate and pyruvate) rather than the substrate (alanine). The shift to the alanine aminotransferase nomenclature occurred gradually through the 1980s and 1990s as the systematic IUPAC enzyme nomenclature became the international standard. Older patients and some European laboratories may still report SGPT; this is the same enzyme as alanine aminotransferase.

Back to Table of Contents

Why Alanine Aminotransferase Is the Most Liver-Specific Routine Marker

Alanine aminotransferase's clinical usefulness depends on two facts:

Aspartate aminotransferase is the more revealing contrast. Aspartate aminotransferase is also abundant in liver, but is equally abundant in skeletal muscle, cardiac muscle, kidney, brain, and red blood cells. Hemolysis during phlebotomy can artifactually elevate aspartate aminotransferase. Vigorous exercise can elevate aspartate aminotransferase significantly. Acute myocardial infarction historically caused dramatic aspartate aminotransferase elevations (which is why aspartate aminotransferase was originally used as a cardiac marker before cardiac-specific troponins came along). All of these confounders are absent or markedly reduced for alanine aminotransferase.

The clinical inference is that an isolated alanine aminotransferase elevation almost always reflects hepatocyte injury, while an aspartate aminotransferase elevation is always interpreted in light of possible non-hepatic sources. This is the basis for the diagnostic primacy of alanine aminotransferase in hepatology workups and for the aspartate aminotransferase:alanine aminotransferase ratio as a discriminator (see below).

There are a few specific exceptions worth mentioning:

Back to Table of Contents

The Normal Range Controversy (40 U/L vs 19/30 U/L)

The standard laboratory "normal range" for alanine aminotransferase is typically reported as up to 40 U/L (some labs use up to 35 U/L). These ranges were originally derived in the 1970s from blood donor populations that, in retrospect, included many subjects with subclinical non-alcoholic fatty liver disease and chronic viral hepatitis (then unrecognized). The result is that the "normal range" was set too high — many subjects within the reported normal range actually had liver pathology.

The Prati 2002 Annals of Internal Medicine study redefined healthy alanine aminotransferase ranges using a much more rigorously screened reference population (blood donors with no clinical or laboratory evidence of liver disease, no body mass index (BMI) above 25, no metabolic syndrome). The Prati cutoffs are:

The study drew on 6,835 first-time blood donors and tested the new limits in donors with hepatitis C antibodies. The lower limits caught more of the people with hepatitis C virus in their blood (sensitivity 76.3% versus 55% with the older limits), at the price of flagging more people without it (specificity 88.5% versus 97.4%). The extra people caught mostly had minimal to mild liver changes on biopsy.

The Prati cutoffs have not been universally adopted by clinical laboratories, partly because the implications are uncomfortable: applying the stricter cutoffs to the general population reclassifies a substantial fraction of presumably-healthy adults as having mildly abnormal alanine aminotransferase. The National Health and Nutrition Examination Survey (NHANES) population data show that roughly 20-30% of US adults have alanine aminotransferase above the Prati upper limit, which corresponds well to the prevalence of non-alcoholic fatty liver disease established by hepatic ultrasound and biopsy studies.

By these updated figures, an alanine aminotransferase of 35 U/L — clearly within the standard 40 U/L reporting cutoff — is above the healthy range, a point raised especially for women and for people with metabolic risk factors. The 2017 American College of Gastroenterology (ACG) Clinical Guideline (Kwo et al.) gives its own figures, close to Prati's: a true healthy normal level of 29 to 33 IU/L for males and 19 to 25 IU/L for females, with levels above this to be assessed. Those figures are lower than the 40 U/L many laboratories report as "normal."

A common clinical rule of thumb built on these limits reads:

Back to Table of Contents

Interpretation by Magnitude of Alanine Aminotransferase Elevation

The magnitude of alanine aminotransferase elevation correlates roughly with the type of underlying liver pathology, providing a useful clinical heuristic:

The rate of change of alanine aminotransferase is also informative. Acute hepatitis typically rises over days and then falls predictably as the injury resolves. Chronic liver disease typically shows stable mildly-elevated values over months. A sudden rise in a previously stable alanine aminotransferase prompts workup for a new injury (drug, infection, ischemic event).

Back to Table of Contents

The Aspartate Aminotransferase:Alanine Aminotransferase Ratio — Alcoholic vs Non-Alcoholic Patterns

The ratio of aspartate aminotransferase to alanine aminotransferase (often called the De Ritis ratio after the Italian biochemist who first proposed it in 1957) provides important diagnostic information about the underlying liver process:

The Williams-Hoofnagle 1988 Gastroenterology paper expanded the diagnostic value of the aspartate aminotransferase:alanine aminotransferase ratio specifically for cirrhosis assessment: as liver disease progresses from chronic active inflammation to cirrhosis, the aspartate aminotransferase:alanine aminotransferase ratio rises regardless of the original etiology. Its 177 patients all had nonalcoholic chronic liver disease and a liver biopsy. Among 100 with chronic hepatitis B, the mean ratio was 0.59 without cirrhosis and 1.02 with cirrhosis, and it often rose above 1.0 when cirrhosis first became apparent. As an illustration not taken from that paper, a non-alcoholic steatohepatitis patient who starts with aspartate aminotransferase:alanine aminotransferase of 0.7 may have aspartate aminotransferase:alanine aminotransferase of 1.4 by the time non-alcoholic steatohepatitis-related cirrhosis develops. This makes serial aspartate aminotransferase:alanine aminotransferase trending useful for monitoring chronic liver disease progression.

The clinical use of the De Ritis ratio is therefore twofold: (1) initial differential diagnosis of acute or chronic liver disease (alcoholic vs non-alcoholic, principally), and (2) monitoring chronic liver disease progression toward cirrhosis. Both uses are based on the same biochemistry — the differential B6-cofactor dependence of alanine aminotransferase vs aspartate aminotransferase, modulated by the underlying disease's effect on hepatic protein synthesis.

Back to Table of Contents

Non-Alcoholic Fatty Liver Disease — The Global Liver Disease Epidemic

Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic-dysfunction-associated steatotic liver disease (MASLD) in the 2023 multi-society consensus, has become the leading cause of chronic liver disease worldwide. The Younossi 2016 Hepatology meta-analysis estimated global prevalence at approximately 25% of adults, with substantial regional variation: about 32% in South America, 27% in Asia, 24% in North America, 24% in Europe, and 31% in the Middle East. A 2023 update led by the same author pooled 92 studies and put the figure at 30.05% across 1990-2019, rising from 25.26% in 1990-2006 to 38.00% in 2016-2019. In the United States, the National Health and Nutrition Examination Survey data suggest that 30-40% of adults have hepatic steatosis on imaging, of whom an estimated 5-10% have progressed to the more severe non-alcoholic steatohepatitis with active inflammation and fibrosis.

Non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease is best understood as the hepatic manifestation of metabolic syndrome — the cluster of central obesity, insulin resistance, atherogenic dyslipidemia, hypertension, and type 2 diabetes that has become the dominant chronic disease pattern in developed and rapidly developing economies. The pathophysiology involves:

  1. Excess hepatic fatty acid delivery — from dietary fat, from de novo lipogenesis driven by chronic hyperinsulinemia, and from accelerated lipolysis of insulin-resistant visceral adipose tissue. The hepatocyte's capacity to package and export triglyceride as very-low-density lipoprotein (VLDL) is exceeded.
  2. Hepatic triglyceride accumulation — visible as macrovesicular steatosis on biopsy and as hepatic steatosis on ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI).
  3. Lipotoxicity-induced hepatocyte injury — the accumulated free fatty acids, diacylglycerols, and ceramides activate inflammatory cytokine production and apoptotic pathways. Cell death releases alanine aminotransferase into the circulation.
  4. Hepatic stellate cell activation — the wound-healing response to chronic hepatocyte injury produces collagen deposition and progressive fibrosis. Over years to decades, this can progress to cirrhosis.

Alanine aminotransferase elevation is the most accessible biochemical signal of this process, but alanine aminotransferase has poor sensitivity for non-alcoholic fatty liver disease. The Mofrad 2003 study compared 51 biopsied patients who had non-alcoholic fatty liver disease and normal alanine aminotransferase with 50 who had raised values, and found the whole range of liver damage in both: 12 of the 51 had bridging fibrosis and 6 had cirrhosis. A figure of approximately 20% of patients is sometimes given for severe disease with normal values; that study reports no population percentage. The implication is that a normal alanine aminotransferase does not exclude non-alcoholic fatty liver disease — imaging (ultrasound, magnetic resonance imaging proton density fat fraction (MRI-PDFF), or transient elastography) is needed when the clinical suspicion is high (body mass index > 30, type 2 diabetes, metabolic syndrome features).

Management of non-alcoholic fatty liver disease is currently behavioral and pharmacological:

For more on non-alcoholic fatty liver disease, see our pages on Metabolic Syndrome and Liver Disease.

Back to Table of Contents

Recent Drug Trials in Steatohepatitis With Liver Scarring

Three trials report repeat liver biopsy results in adults with metabolic dysfunction-associated steatohepatitis (MASH), the newer name for non-alcoholic steatohepatitis, and liver scarring (fibrosis).

Back to Table of Contents

Drug-Induced Liver Injury (DILI)

Drug-induced liver injury is the most common cause of acute liver failure in the developed world and a frequent cause of elevated alanine aminotransferase. Hundreds of medications and herbal products have been implicated. The patterns of injury fall into three principal categories:

Specific medications worth knowing:

The standard approach to suspected drug-induced liver injury is the modified Roussel-Uclaf Causality Assessment Method (RUCAM), which scores the temporal relationship, exclusion of other causes, risk factors, response to dechallenge, and prior knowledge of hepatotoxicity to estimate the probability that a specific agent caused the observed injury.

Back to Table of Contents

Viral Hepatitis Pattern

Viral hepatitis remains an important cause of alanine aminotransferase elevation worldwide. The clinical context and serology determine the workup:

The standard initial viral panel for an unexplained alanine aminotransferase elevation is hepatitis B surface antigen, hepatitis C virus antibody, and (in appropriate clinical settings) hepatitis A virus immunoglobulin M antibody and human immunodeficiency virus (HIV) antibody.

Back to Table of Contents

Practical Workup of an Isolated Alanine Aminotransferase Elevation

The Kwo 2017 ACG Clinical Guideline and the Newsome 2018 British Society of Gastroenterology (BSG) guideline both provide structured approaches to the patient with an isolated alanine aminotransferase elevation. A practical synthesis:

  1. Confirm and characterize — the liver function tests are repeated to show whether the elevation is real and not laboratory artifact. The aspartate aminotransferase:alanine aminotransferase ratio and the R-value (described above) are calculated. International normalized ratio and albumin are checked for synthetic function assessment.
  2. History — alcohol intake (the Alcohol Use Disorders Identification Test-Consumption questionnaire, AUDIT-C), medication and herbal supplement use, intravenous (IV) drug use risk factors, sexual risk factors, travel history, family history of liver disease, occupational exposures, prior episodes of jaundice, autoimmune disease history.
  3. Physical examination — body mass index and waist circumference (metabolic syndrome), stigmata of chronic liver disease (palmar erythema, spider angiomata, gynecomastia, ascites, splenomegaly), Kayser-Fleischer rings (Wilson disease), arthritis (autoimmune hepatitis association).
  4. First-tier laboratory workup — metabolic panel (fasting glucose, hemoglobin A1c, lipid panel for non-alcoholic fatty liver disease risk stratification), hepatitis B surface antigen, hepatitis C virus antibody, ferritin and transferrin saturation (hemochromatosis), antinuclear antibody (ANA) and anti-smooth muscle antibody (ASMA) (autoimmune hepatitis), tissue transglutaminase immunoglobulin A (IgA) (celiac).
  5. Imaging — abdominal ultrasound for hepatic steatosis, biliary tree, and any focal lesions. Magnetic resonance imaging proton density fat fraction if quantitative steatosis assessment is needed. Transient elastography if fibrosis assessment is needed (non-alcoholic fatty liver disease >F2 fibrosis is a hepatology referral trigger).
  6. Second-tier workup if first-tier negative — ceruloplasmin and 24-hour urinary copper (Wilson disease), alpha-1 antitrypsin level and Pi typing (alpha-1 antitrypsin deficiency), thyroid function (hypothyroidism-associated non-alcoholic fatty liver disease), human immunodeficiency virus testing, repeat viral hepatitis panel including hepatitis E virus in appropriate clinical contexts.
  7. Specialty referral — alanine aminotransferase more than 5 times the upper limit of normal despite negative initial workup; persistent alanine aminotransferase elevation >6 months without identified cause; any patient with cirrhosis or significant fibrosis (non-alcoholic fatty liver disease >F2); fulminant presentation (rising international normalized ratio, encephalopathy, jaundice).
  8. Liver biopsy — rarely needed in modern hepatology due to advances in non-invasive imaging and serological scoring. Indicated when the diagnosis remains unclear after the second-tier workup, or when management decisions require histological staging.

The most common ultimate diagnosis for an isolated mildly-elevated alanine aminotransferase in a developed-world primary care population is non-alcoholic fatty liver disease, followed by chronic viral hepatitis (B or C), alcoholic liver disease, drug-induced injury, and autoimmune hepatitis. The rarer diagnoses (Wilson disease, alpha-1 antitrypsin deficiency, hemochromatosis) are specifically looked for in younger patients without obvious metabolic or behavioral risk factors.

Back to Table of Contents

The Alanine Load Test for Hepatic Function

The alanine load test is a research-grade assessment of hepatic functional reserve that uses an oral alanine dose (15-30 g) to challenge the gluconeogenic capacity of the liver. The post-load plasma glucose and alanine kinetics provide a sensitive measure of hepatic gluconeogenic capacity that is impaired earlier than conventional liver function markers.

In healthy subjects, oral alanine produces a brisk rise in plasma alanine peaking at 60-90 minutes, with proportional plasma glucose rise and glucagon secretion. The plasma alanine clearance half-life is approximately 90 minutes. The test was originally developed in the 1970s from Genuth's 1973 work in fasting obese subjects and Genuth and Castro's 1974 work in normal and diabetic subjects, and subsequently adapted for research evaluation of hepatic function in cirrhosis, non-alcoholic steatohepatitis, and post-bariatric patients.

The alanine load test is rarely used in routine clinical hepatology because non-invasive imaging (magnetic resonance imaging elastography, transient elastography) and validated scoring systems (Fibrosis-4 index (FIB-4), non-alcoholic fatty liver disease Fibrosis Score, aspartate aminotransferase-to-platelet ratio index (APRI)) provide more practical assessments of hepatic function and fibrosis. The test remains useful in research settings where dynamic gluconeogenic capacity is the specific question of interest.

For patients curious about alanine's metabolic role in their own physiology, the clinical correlate is simpler: a standard glucose tolerance test (oral 75 g glucose with serial glucose and insulin measurements) implicitly assesses the post-load alanine response as part of the integrated postprandial metabolic state. Reactive hypoglycemia identified on a glucose tolerance test often reflects impaired alanine-mediated gluconeogenic counter-regulation.

Back to Table of Contents

Cautions

Back to Table of Contents

Key Research Papers

  1. Pratt DS, Kaplan MM (2000). Evaluation of abnormal liver-enzyme results in asymptomatic patients. NEJM 342(17):1266-1271. — DOI: 10.1056/NEJM200004273421707. — doi:10.1056/NEJM200004273421707
  2. Prati D, Taioli E, Zanella A, et al. (2002). Updated definitions of healthy ranges for serum alanine aminotransferase levels. Annals of Internal Medicine 137(1):1-10. — DOI: 10.7326/0003-4819-137-1-200207020-00006. — doi:10.7326/0003-4819-137-1-200207020-00006
  3. Kwo PY, Cohen SM, Lim JK (2017). ACG Clinical Guideline: Evaluation of abnormal liver chemistries. American Journal of Gastroenterology 112(1):18-35. — DOI: 10.1038/ajg.2016.517. — doi:10.1038/ajg.2016.517
  4. Newsome PN, Cramb R, Davison SM, et al. (2018). Guidelines on the management of abnormal liver blood tests. Gut 67(1):6-19. — DOI: 10.1136/gutjnl-2017-314924. — doi:10.1136/gutjnl-2017-314924
  5. Younossi ZM, Koenig AB, Abdelatif D, et al. (2016). Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment. Hepatology 64(1):73-84. — DOI: 10.1002/hep.28431. — doi:10.1002/hep.28431
  6. Cohen JC, Horton JD, Hobbs HH (2011). Human fatty liver disease: old questions and new insights. Science 332(6037):1519-1523. — DOI: 10.1126/science.1204265. — doi:10.1126/science.1204265
  7. Mofrad P, Contos MJ, Haque M, et al. (2003). Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37(6):1286-1292. — DOI: 10.1053/jhep.2003.50229. — doi:10.1053/jhep.2003.50229
  8. Williams ALB, Hoofnagle JH (1988). Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis — relationship to cirrhosis. Gastroenterology 95(3):734-739. — DOI: 10.1016/s0016-5085(88)80022-2. — doi:10.1016/s0016-5085(88)80022-2
  9. Cohen JA, Kaplan MM (1979). The SGOT/SGPT ratio — an indicator of alcoholic liver disease. Digestive Diseases and Sciences 24(11):835-838. — DOI: 10.1007/BF01324898. — doi:10.1007/BF01324898
  10. Sookoian S, Pirola CJ (2012). Alanine and aspartate aminotransferase and glutamine-cycling pathway: their roles in pathogenesis of metabolic syndrome. World Journal of Gastroenterology 18(29):3775-3781. — DOI: 10.3748/wjg.v18.i29.3775. — doi:10.3748/wjg.v18.i29.3775
  11. Cohen DE, Anania FA, Chalasani N (2006). An assessment of statin safety by hepatologists. American Journal of Cardiology 97(8A):77C-81C. — DOI: 10.1016/j.amjcard.2005.12.014. — doi:10.1016/j.amjcard.2005.12.014
  12. Larson AM, Polson J, Fontana RJ, et al. (2005). Acetaminophen-induced acute liver failure: results of a US multicenter, prospective study. Hepatology 42(6):1364-1372. — DOI: 10.1002/hep.20948. — doi:10.1002/hep.20948
  13. Chalasani N, Younossi Z, Lavine JE, et al. (2018). The diagnosis and management of NAFLD: practice guidance from AASLD. Hepatology 67(1):328-357. — DOI: 10.1002/hep.29367. — doi:10.1002/hep.29367
  14. Genuth SM, Castro J (1974). Effect of oral alanine on blood beta-hydroxybutyrate and plasma glucose, insulin, free fatty acids, and growth hormone in normal and diabetic subjects. Metabolism 23(4):375-386. — PubMed PMID: 4206148
  15. Genuth SM (1973). Effects of oral alanine administration in fasting obese subjects. Metabolism 22(7):927-937. — PubMed PMID: 4710700
  16. Younossi ZM, Golabi P, Paik JM, et al. (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77(4):1335-1347. — PubMed PMID: 36626630
  17. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. (2015). Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149(2):367-378. — PubMed PMID: 25865049
  18. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH (1988). Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). NEJM 319(24):1557-1562. — PubMed PMID: 3059186
  19. Sanyal AJ, Newsome PN, Kliers I, et al. (2025). Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. NEJM 392(21):2089-2099. — PubMed PMID: 40305708
  20. Harrison SA, Bedossa P, Guy CD, et al. (2024). A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. NEJM 390(6):497-509. — PubMed PMID: 38324483
  21. Loomba R, Hartman ML, Lawitz EJ, et al. (2024). Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. NEJM 391(4):299-310. — PubMed PMID: 38856224
  22. Dolan E, Swinton PA, Painelli VS, et al. (2019). A systematic risk assessment and meta-analysis on the use of oral beta-alanine supplementation. Advances in Nutrition 10(3):452-463. — PubMed PMID: 30980076

PubMed Topic Searches

  1. PubMed: ALT and liver function testing
  2. PubMed: AST:ALT (De Ritis) ratio in liver disease
  3. PubMed: NAFLD/NASH and ALT
  4. PubMed: Drug-induced liver injury (DILI)
  5. PubMed: Prati healthy ALT cutoffs
  6. PubMed: Acetaminophen hepatotoxicity

Back to Table of Contents

Connections

Back to Table of Contents